SLC5A2 and heart failure: In EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with a Reduced Ejection Fraction), patients with heart failure with reduced ejection fraction were randomized to receive another sodium glucose co-transporter 2 (SGLT2) inhibitor, empagliflozin, or placebo.13